News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
25.81
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at Piper Sandler Healthcare Conference
November 22, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Where Ultragenyx Pharmaceutical Stands With Analysts
↗
November 03, 2022
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:
Via
Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
↗
July 29, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:
Via
Benzinga
Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance
↗
July 29, 2022
Via
Benzinga
Ultragenyx Announces Departure of Chief Financial Officer
November 10, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at Upcoming Healthcare Conferences
November 09, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
↗
November 03, 2022
Upgrades
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
November 09, 2022
On Wednesday, 283 companies set new 52-week lows.
Via
Benzinga
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
November 02, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
↗
November 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
October 27, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Earnings Scheduled For November 2, 2022
↗
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
↗
October 13, 2022
Upgrades
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
September 14, 2022
During Wednesday's session, 265 companies made new 52-week lows.
Via
Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
↗
August 18, 2022
Gainers
Via
Benzinga
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
August 18, 2022
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results.
Via
Benzinga
NVIDIA, Tyson Foods, BioNTech And Some Other Big Stocks Moving Lower On Monday
↗
August 08, 2022
AMTD Digital Inc. (NYSE: HKD) dipped 21.8% to $563.71 on possible profit taking after the stock surged over the last few trading days.
Via
Benzinga
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
July 29, 2022
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q2 Earnings
↗
July 28, 2022
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
↗
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
↗
August 01, 2022
Upgrades
Via
Benzinga
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees 'Viable Path Forward"
↗
July 19, 2022
Via
Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
↗
July 19, 2022
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday.
Via
Benzinga
Earnings Scheduled For July 28, 2022
↗
July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.
Via
Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
↗
July 20, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 19, 2022
Via
Benzinga
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
↗
July 19, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.